Clinical observation of modified DCF regimen versus FOLFOX 4 regimen as first-line treatment for ad-vanced gastric cancer
Objective To evaluate the efficacy and toxicity of modified DCF regimen compared with FOLFOX 4 regimen as the first-line treatment for patients with advanced gastric cancer. Methods Form January 2010 to July 2013, 47 advanced gastric car-cinoma patients were enrolled in this study. Twenty-four patients received modified DCF regimen( docetaxel 60mg/m2 iv,d1;oxaliplatin 100mg/m2 iv, d1;fluorouracil 400 mg/m2 iv, d1-d2;fluorouracil 600 mg/m2 civ 48h, d2-d3;21 days was a cycle) and 23 patients re-ceived FOLFOX 4 regimen( oxaliplatin 85mg/m2 iv,d1; calcium folinate 200mg/m2 iv, d1-d2; fluorouracil 400mg/m2 iv, d1-d2; flu-orouracil 600 mg/m2 civ 22h;14 days was a cycle) . The efficacy was evaluated every 6 weeks. The response rate( RR) , disease con-trol rate(DCR), progression-free survival(PFS)and overall survival(OS)were analyzed between the two groups. Results Efficacy could be evaluated in all patients. Patients in modified DCF group achieved PR in 6 cases, SD in 16 cases and PD in 2 cases with RR of 25?0% and DCR of 91?6%. Patients in FOLFOX 4 group achieved PR in 2 cases, SD in 16 cases and PD in 5 cases with RR of 8?6% and DCR of 78?2%. The differences of DCR and RR between the two groups had no significance( P>0?05) . Meanwhile, the me-dian PFS and OS were 8?2 and 11?5 months in modified DCF group and 5?8 and 10?1 months in FOLFOX 4 group with no significant differences( P>0?05) . The main toxicities were myelosuppression and digestive tract reaction, mainly in grade 1-2, and the incidence of the two groups had no differences( P>0?05) . Conclusion There are similar efficacy and toxicities between modified DCF regimen and FOLFOX 4 regimen, which is worth further study.
NETL
NSTL
万方数据
维普
